Escitalopram for Premenstrual Syndrome (PMS) in Teens: A Pilot Study

Phase 4

Terminated

Brief Summary: The purpose of this pilot study is to determine the efficacy and safety of escitalopram administered premenstrually (day 14 through day 2 of the menstrual cycle) for severe PMS in young women ages 15-19 years.

Detailed Description: The medication in this study is a serotonin reuptake inhibitor (SSRI), a class that is considered the first-line treatment for severe PMS at this time. Although data indicate that young women who have PMS in their teen years report the same symptoms and symptom severity as adult women, clinical trials have not included this age group, and there is no information on the efficacy and safety of treatment with a serotonergic antidepressant for PMS in teens.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

Current use of any treatment for PMS.
Psychotropic or other medications that may compromise the study drug.
Pregnancy, intending pregnancy or breast feeding.
Not using a medically approved birth control method if sexually active.
Significant medical or gynecological abnormalities.
Irregular menses, any gynecologic disorder.
Any severe or unstable medical illness.
Any current major psychiatric diagnosis or any history of a major psychiatric diagnosis.
Any current or history of alcohol abuse, drug abuse, suicide attempt, bi-polar disorder, psychosis or severe personality disorder.
Use of triptans (Imitrex, Zomig, Frova, Maxalt, Axert, Amerge, Relpax).
Use of medicines that include dextromethorphan such as Tylenol or Vicks cough medicines.
Use of the pain medication meperidine.
Use of any herbal product such as St John's Wort that may increase serotonin.
Use of monoamine oxidase inhibitors (MAOIs), pimozide or citalopram hydrobromide.
Drugs metabolized by CYP2D6 or a combination of CYP3A4 and CYP2D6 inhibitors.
Hypersensitivity to escitalopram or citalopram.

Arm && Interventions

Group	Intervention	Description
escitalopram	escitalopram	Escitalopram 10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
placebo	placebo	Placebo tablets matched to drug.

Primary Outcome Measures

Name	Time	Method
Subject Daily Symptom Rating Score.	baseline and 5 months.	A daily diary with 17 symptoms of PMS rated on a 5-point scale to indicate none to very severe symptoms. Minimum score 0; maximum score 408.

Secondary Outcome Measures

Name	Time	Method
Sheehan Disability Scale (SDS)	Throughout study
Patient Global Evaluation of Improvement (PGE)	Throughout treatment
Subject Satisfaction Questionnaire	Study endpoint